• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Should J&J’s Oncology and MedTech Breakthroughs Prompt a Fresh Look From Johnson & Johnson (JNJ) Investors?

    Simply Wall St·07/26/2026 06:21:02
    Listen to the news
    • Johnson & Johnson recently reported strong second-quarter 2026 results, lifted its full-year sales outlook to US$100.80 billion–US$101.40 billion, and announced positive Phase 3 MonumenTAL-6 data showing that TECVAYLI plus TALVEY and TALVEY plus pomalidomide improved progression-free and overall survival in relapsed or refractory multiple myeloma versus standard care.
    • Combined with De Novo FDA authorization for its OTTAVA table-integrated robotic surgical system, these advances highlight how Johnson & Johnson is pushing deeper into high-value oncology therapies and next-generation MedTech platforms at the same time.
    • We’ll now examine how the strong MonumenTAL-6 oncology data could reshape Johnson & Johnson’s investment narrative around future drug growth and resilience.

    Find 49 companies with promising cash flow potential yet trading below their fair value.

    Johnson & Johnson Investment Narrative Recap

    To own Johnson & Johnson today, you really have to believe that its Innovative Medicine engine, especially oncology, can offset patent losses and ongoing legal and tariff headwinds. The MonumenTAL-6 data strengthens the idea that multiple myeloma could remain a core pillar of that story, but it does not remove near term pressure from STELARA biosimilars or talc litigation, which still look like the key short term swing factors for the equity narrative.

    Against that backdrop, the De Novo FDA authorization for the OTTAVA robotic surgical system fits neatly with the pipeline news, showing J&J pushing both oncology drugs and MedTech platforms that analysts have flagged as future growth drivers. While OTTAVA is still in the early stages of rollout, it matters for the same reason MonumenTAL-6 does: both speak to how much confidence you place in J&J’s ability to replace aging revenue with higher value innovation.

    Yet despite these advances, investors should still be aware of how STELARA biosimilars and unresolved talc cases could...

    Read the full narrative on Johnson & Johnson (it's free!)

    Johnson & Johnson's narrative projects $116.6 billion revenue and $26.9 billion earnings by 2029. This requires 6.6% yearly revenue growth and about a $5.9 billion earnings increase from $21.0 billion today.

    Uncover how Johnson & Johnson's forecasts yield a $252.87 fair value, a 4% downside to its current price.

    Exploring Other Perspectives

    JNJ 1-Year Stock Price Chart
    JNJ 1-Year Stock Price Chart

    Some of the lowest ranked analysts were already assuming only about US$114.4 billion of revenue and US$22.6 billion of earnings by 2029, and they also worry that oncology workhorses like TECVAYLI and TALVEY could face payer and competition pressure that blunts gains from studies like MonumenTAL-6, which shows how far apart views on Johnson & Johnson’s upside can still be.

    Explore 7 other fair value estimates on Johnson & Johnson - why the stock might be worth as much as 47% more than the current price!

    The Verdict Is Yours

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    • A great starting point for your Johnson & Johnson research is our analysis highlighting 3 key rewards that could impact your investment decision.
    • Our free Johnson & Johnson research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Johnson & Johnson's overall financial health at a glance.

    Looking For Alternative Opportunities?

    Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.